AS 601245

Drug Profile

AS 601245

Latest Information Update: 14 Dec 2006

Price : $50

At a glance

  • Originator Merck Serono
  • Class Small molecules
  • Mechanism of Action Mitogen-activated protein kinase 10 inhibitors; Mitogen-activated protein kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation; Ischaemia

Most Recent Events

  • 22 Dec 2004 Phase-I clinical trials in Ischaemia in Switzerland (PO)
  • 22 Dec 2004 Phase-I clinical trials in Inflammation in Switzerland (PO)
  • 22 Sep 2004 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top